BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report)’s stock price traded down 3.8% on Tuesday. The stock traded as low as C$10.60 and last traded at C$10.60. 3,402 shares traded hands during trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Trading Down 3.8%
The stock has a market capitalization of C$168.68 million and a price-to-earnings ratio of -28.19. The business has a 50-day moving average of C$10.60 and a 200-day moving average of C$10.60. The company has a debt-to-equity ratio of 0.05, a quick ratio of 128.68 and a current ratio of 129.63.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
